This is a preview of subscription content, log in via an institution to check access.
Notes
funded by Novartis Pharmaceuticals
Reference
Tremblay G, et al. Cost?-Effectiveness Analysis of Midostaurin (Mido) with Standard of Care (Soc) for Acute Myeloid Leukemia (Aml) in Canada. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN103, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/82035?pdfid=54838
Rights and permissions
About this article
Cite this article
Midostaurin a cost-effective option for AML in Canada. PharmacoEcon Outcomes News 805, 23 (2018). https://doi.org/10.1007/s40274-018-5025-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5025-9